spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  fibrinolytic 

 HSMN NewsFeed - 28 May 2021
IRRAS Announces publication of a Case report from Buffalo General Medical Center, highlights clinical superiority of IRRAflow treatment versus traditional drainage
Devices Neurosurgery Monitoring
 HSMN NewsFeed - 11 Jul 2017
Prometic Announces Positive Long Term Clinical Data on Ryplazym(TM) in Plasminogen Congenital Deficiency and Provides Regulatory Update
Biopharmaceuticals
 HSMN NewsFeed - 27 Jun 2014
Eliquis(R) (apixaban) Receives CHMP Positive Opinion for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 12 May 2014
FDA Approves ZONTIVITY(TM) (vorapaxar), First-in-Class PAR-1 Antagonist, for the Reduction of Thrombotic Cardiovascular Events in Patients with a History of Heart Attack or with Peripheral Arterial Disease
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 21 Feb 2014
In a Subanalysis, Eliquis(R) (apixaban) Reduced the Risk of Stroke and Demonstrated Fewer Major Bleeding Events versus Warfarin Consistently across Age Groups, Including Older Patients with Nonvalvular Atrial Fibrillation
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 19 Dec 2013
Baxter Receives FDA Approval of FEIBA [Anti-Inhibitor Coagulant Complex] for Prophylactic Treatment of Hemophilia A&B Patients with Inhibitors
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Sep 2013
Subanalysis of Phase III ARISTOTLE Trial of Eliquis(R) (apixaban) Demonstrated Consistent Results Versus Warfarin in Patients with Nonvalvular Atrial Fibrillation with or without Valvular Heart Disease
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 28 Aug 2013
FDA Accepts Boehringer Ingelheim's Supplemental New Drug Application for Use of Dabigatran Etexilate Mesylate in Deep Vein Thrombosis and Pulmonary Embolism
Biopharmaceuticals FDA
 HSMN NewsFeed - 23 Jul 2013
Instrumentation Laboratory Launches HemosIL(R) FDP Assay In Europe, Asia And Other International Regions
Diagnostics Product Launch
 HSMN NewsFeed - 7 Nov 2012
URGENT NOTICE -- DRUG RECALL: Boehringer Ingelheim Pharmaceuticals, Inc. Initiates a Voluntary Recall of a Single Manufacturing Lot of Pradaxa(R) (dabigatran etexilate mesylate) Capsules 75mg in the U.S. and Puerto Rico
Biopharmaceuticals Cardiology Product Recall
 HSMN NewsFeed - 26 Aug 2011
Boehringer Ingelheim to Launch RE-ALIGN Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 20 Oct 2010
FDA Approves Pradaxa, Marking a Major Milestone to Reduce the Risk of Stroke in Patients with Non-Valvular Atrial Fibrillation
Biopharmaceuticals Cardiology Neurology FDA
 HSMN NewsFeed - 10 May 2010
Ferring Acquires LYSTEDA(TM) From Xanodyne Pharmaceuticals, Inc.
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 9 Mar 2010
Bristol-Myers Squibb and AstraZeneca Announce the Commencement of the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus Trial (SAVOR-TIMI 53)
Biopharmaceuticals Cardiology Endocrinology
 HSMN NewsFeed - 11 Jan 2010
ViroPharma Expands Global Licensing, Commercialization and Development Rights for Cinryze(TM) (C1 esterase inhibitor [human])
Biopharmaceuticals Licensing
 HSMN NewsFeed - 2 Apr 2009
Xanodyne's New Drug Application for the Treatment of Heavy Menstrual Bleeding (Menorrhagia) Accepted for Filing with a Priority Review Classification
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Feb 2009
FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE)
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 Oct 2008
ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 15 Jul 2008
ViroPharma To Acquire Lev Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 6 May 2008
Lev Pharmaceuticals Announces Cinryze(TM) Complete Response Submission Accepted for Review by FDA
Biopharmaceuticals FDA
 HSMN NewsFeed - 2 May 2008
Lev Announces FDA Advisory Committee Unanimously Recommends Approval of Cinryze(TM) for Hereditary Angioedema
Biopharmaceuticals FDA
 HSMN NewsFeed - 15 Apr 2008
Lev Pharmaceuticals Announces Submission of Complete Response to FDA for Cinryze(TM) for Hereditary Angioedema
Biopharmaceuticals
 HSMN NewsFeed - 4 Feb 2008
EKR Therapeutics and PDL BioPharma Sign Asset Purchase Agreement for Cardiovascular Products
Biopharmaceuticals Acquisitions Cardiology
 HSMN NewsFeed - 12 Dec 2007
Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke
Biopharmaceuticals Neurology Interventional
 HSMN NewsFeed - 21 Oct 2007
Plavix(R) Indications Expanded in Japan to Include Patients with Acute Coronary Syndrome for Whom Percutaneous Coronary Intervention Is Being Planned
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 10 Sep 2007
Lev Pharmaceuticals Meets Primary Endpoint in Pivotal Phase III Prophylactic Trial for Hereditary Angioedema
Biopharmaceuticals
 HSMN NewsFeed - 2 Sep 2007
New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 22 Aug 2007
Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
Biopharmaceuticals
 HSMN NewsFeed - 26 Jun 2007
Nuvelo Resumes Development of Alfimeprase in Multiple Blood-Clot Related Indications
Biopharmaceuticals
 HSMN NewsFeed - 5 Jun 2007
Health Canada's approval of an expanded indication for PLAVIX(R) (clopidogrel bisulfate) now offers protection from all types of heart attacks
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 18 May 2007
FDA Approves Lovenox(R) (Enoxaparin Sodium Injection) for the Most Severe Type of Heart Attack
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 7 Feb 2007
FDA Grants Priority Review to Lovenox(R) (Enoxaparin Sodium Injection) Supplemental New Drug Application (sNDA) for Acute Heart Attack
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 9 Nov 2006
Neurobiological Technologies, Inc. Comments on Recent Stroke Trial Developments
Biopharmaceuticals Neurology
 HSMN NewsFeed - 6 Nov 2006
Nuvelo Announces Presentations on Alfimeprase and rNAPc2 at The American Heart Association Scientific Sessions 2006
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 1 Nov 2006
MediciNova Announces the Acquisition of Two Novel Antithrombotic Agents from Meiji Seika Kaisha, Ltd.
Biopharmaceuticals Cardiology Acquisitions
 HSMN NewsFeed - 7 Sep 2006
European commission expands indication for PLAVIX® (clopidogrel bisulfate) offering new option for patients with most severe type of heart attack
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 5 Sep 2006
New Clinical Data Show Enoxaparin Significantly Reduced the Risk of Repeat Heart Attack and Stroke in Patients Undergoing Percutaneous Coronary Intervention (PCI)
Biopharmacetuicals Cardiology
 HSMN NewsFeed - 4 Sep 2006
New Clinical Data Show Enoxaparin Significantly Reduces the Risk of Repeat Heart Attacks and Stroke in Patients Undergoing Percutaneous Coronary Intervention (PCI)
Biopharmaceuticals Interventional Cardiology
 HSMN NewsFeed - 24 Aug 2006
Neurobiological Technologies, Inc. Announces Completion of Targeted U.S. Site Selection for Its First Viprinex(TM) (Ancrod Injection) Phase III Clinical Trial for Acute Ischemic Stroke
 HSMN NewsFeed - 22 Mar 2006
Neurobiological Technologies Inc. Announces Initiation of Second Viprinex(TM) (Ancrod) Phase III Clinical Trial for Acute Ischemic Stroke
Biopharmaceuticals Neurology
 HSMN NewsFeed - 14 Mar 2006
Brigham and Women's Cardiac Group Finds Enoxaparin Strategy is Better Than Commonly Administered Blood Thinning Strategy for Heart Attacks
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 20 Jan 2006
Gentium Initiates Phase II/III Pediatric Trial with Defibrotide to Prevent Veno-Occlusive Disease
Biopharmaceuticals
 HSMN NewsFeed - 18 Jan 2006
FDA Grants Priority Review to PLAVIX(R) (Clopidogrel Bisulfate) Supplemental New Drug Application (sNDA) for Additional Type of Heart Attack
Biopharmaceuticals Cardiology FDA
Return to NewsFeed  

 Additional items found! 11

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 11 additional stories matching:
fibrinolytic
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.